Analyst Price Target is $19.33
▲ +48.95% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Enanta Pharmaceuticals in the last 3 months. The average price target is $19.33, with a high forecast of $28.00 and a low forecast of $11.00. The average price target represents a 48.95% upside from the last price of $12.98.
Current Consensus is
The current consensus among 6 contributing investment analysts is to hold stock in Enanta Pharmaceuticals. This Hold consensus rating has held steady for over two years.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.